Skip to content

The Effect of Fortifying the Spleen, Clearing heat, Activating Blood Method on Chronic Atrophic Gastritis: a Real World Study

The Effect of Fortifying the Spleen, Clearing heat, Activating Blood Method on Chronic Atrophic Gastritis: a Real World Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR1900002735
Enrollment
Unknown
Registered
2019-11-03
Start date
2019-12-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Atrophic Gastritis

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, gender without limitation; 2. The diagnosis of chronic atrophic gastritis was confirmed by gastroendoscopy and gastric mucosa histopathology; 3. TCM syndrome was confirmed by standard syndrome differentiation; 4. Hp negative was diagnosied by rapid urease assay or 13C breath test or 14C breath test within nearly 1 month; 5. Be able to normal verbal communication; 6. Auqired the informed consent and willing to be a volunteer.

Exclusion criteria

Exclusion criteria: 1. Participating in other drug treatment studies within the nearly one month; 2. Combined with autoimmune gastritis (type A chronic atrophic gastritis), peptic ulcer (stage A1 -H2), reflux esophagitis, gastric polyp, hypertrophic gastritis, ulcerative colitis, history of gastrointestinal surgery and other disease; 3. Gastric mucosal high-grade intraepithelial neoplasia, gastrointestinal mucosal lesions suspected malignant transformation, gastrointestinal tumors; 4. Patients with malignant tumors undergoing surgery, radiotherapy and chemotherapy in the past 5 years; 5. Combined with serious organic diseases.Such as: heart (cardiac functionNYHIII-IV, hemodynamic unstable myocardial infarction, etc.), liver (decompensated stage of liver cirrhosis, etc.), kidney (chronic renal failure, uremia stage, etc.), lung (tuberculosis, acute attack of asthma, pulmonary infection, etc.), autoimmune system (active stage of systemic lupus erythematosus), etc.; 6. Allergic constitution or allergic to a variety of drugs; 7. With severe mental illness so as to unable to cooperate with researchers, such as schizophrenia, depression, anxiety, dementia and so on; 8. Pregnant, breast feeding women; 9. Uncooperative Investigator.

Design outcomes

Primary

MeasureTime frame
Histopathology;

Secondary

MeasureTime frame
Economic evaluation;Symptom Assessment;Gastroscopy evaluation;Anxiety and deprssion evaluation;Quality of life assessment;Syndrome efficacy evaluation;

Countries

China

Contacts

Public ContactFengbin Liu
liufb163@163.com+86 13694239909

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026